Previous 10 | Next 10 |
By Stephen H. Dover, CFA, Executive Vice President, Head of Equities, Krzysztof Musialik, CFA, Research Analyst, Franklin Templeton Emerging Markets Equity, and Steve Kornfeld, CFA, Portfolio Manager, Research Analyst, Franklin Equity Group The biopharma industry has the potential to save...
In an interview with CNBC, Health Secretary Alex Azar revealed that the Trump administration is working on a plan that would allow the U.S. to import medicines from Canada, but offered no additional details as to how the plan would work. More news on: ProShares Trust - ProShares Ultra Na...
By Andy Acker, CFA & Luyi Guo, Ph.D., CFA & Rich Carney, CFA Last week, the Trump administration abandoned plans to overhaul drug rebates in Medicare while a federal judge ruled against listing prescription drug prices in TV ads. But U.S. drug reform is far from over, with implica...
By Stephen H. Dover, Executive Vice President, Head of Equities; Aman Gupta, Portfolio Manager, Research Analyst, Franklin Mutual Series; Brian DeChristopher, Research Analyst, Franklin Equity Group; Evan McCulloch, Portfolio Manager, Director of Equity Research, Franklin Equity Group; Krzysz...
Major drug makers are under water nearing the close as skittish investors move the sidelines ahead of President Trump's plan to peg Medicare reimbursement to the lowest ex-U.S. prices from a select group of countries. More news on: ProShares Ultra Nasdaq Biotechnology ETF, The Gabelli Heal...
By Andy Acker, CFA Global Life Sciences Portfolio Manager Andy Acker discusses how large-cap biopharmaceutical companies utilize M&A strategies to fill product pipelines and maintain steady cash flows. Transcript Andy Acker : Earlier this week, AbbVie ([[ABBV]])...
By Andy Acker, CFA Global Life Sciences Portfolio Manager Andy Acker discusses how large-cap biopharmaceutical companies utilize M&A strategies to fill product pipelines and maintain steady cash flows. Transcript Andy Acker : Earlier this week, AbbVie ([[ABBV]])...
Today it seems there are very few areas for which Democrats and Republicans agree. On most issues Americans have come to expect little change by congress due to extreme levels of partisanship. One of the few areas where bipartisan consensus is growing is that Pharmaceutical firms are a primary...
Members of Big Biopharma, with the notable exception of AbbVie, are all enjoying a spike in buying after its $63B bid for Allergan, stoking hopes that big healthcare mergers are back in play. More news on: Takeda Pharmaceutical Company Limited, Bausch Health Companies Inc., Roche Holding...
SPDR S&P Pharmaceuticals ETF (NYSEARCA: XPH ) declares quarterly distribution of $0.0683 . 30-Day SEC Yield of 0.60%. Payable June 27; for shareholders of record June 25; ex-div June 24. Press Release More news on: SPDR S&P Pharmaceuticals ETF, Dividend News, , News on ETF...
News, Short Squeeze, Breakout and More Instantly...
SPDR S&P Pharmaceuticals Company Name:
XPH Stock Symbol:
NYSE Market:
Second Quarter 2024 Highlights: Record sales of $3.61 billion, up 18% in U.S. dollars and 11% organically compared to the second quarter of 2023 GAAP Diluted EPS of $0.41, up 11% compared to prior year Record Adjusted Diluted EPS of $0.44, up 22% compared to prior year ...
2024-07-19 12:54:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Transaction highlights: To acquire CommScope’s Outdoor Wireless Networks and Distributed Antenna Systems businesses for $2.1 billion in cash Adds advanced antenna and associated interconnect products, technologies and capabilities Complements Amphenol’s existing prod...